Biotech Daily

Monday November 2, 2026

Daily news on ASX-listed biotechnology companies

*** ASX, BIOTECH DOWN: CYCLOPHARM UP 8%; PROTEOMICS DOWN 24%**

*** OCTOBER BDI-40 DOWN 10%, ASX200 UP 1%, BIG CAPS UP 9%, NBI UP 3%**

*** LITTLE GREEN H1 RECEIPTS UP 113% TO $50m**

*** NEURIZON $4.3m PLACEMENT; $2m SHARE PLAN; SETTLES NOTES**

*** PROTEOMICS $5m SHARE PLAN**

*** NOXOPHARM $1.5m PLACEMENT; $1m SHARE PLAN TO GO**

*** ORTHOCELL RECORD $279k MONTHLY US REMPLIR SALES**

*** ANTERIS: 'NO MEDIUM DURAVR VALVE-RELATED MORTALITY'**

*** NEUREN WINS FDA NNZ-2591 NEO-NATAL HIE ORPHAN DRUG STATUS**

*** PERCHERON: FDA OK FOR VANDERBILT HMBD-002 BLOOD CANCER TRIAL**

*** ONCOSIL FILES FOR AUSTRALIAN MANUFACTURING APPROVAL**

*** NEXSEN WINS STREPSURE ISO13485:2016 STANDARDS CERTIFICATION**

*** INOVIQ EXO-OC SONIC HEALTHCARE VALIDATION**

*** OSTEOPORE ENDS DKSH SINGAPORE ORTHOPAEDIC SALES CONTRACT**

*** VITURA 'NOT LIABLE' FOR CDA CLINICS $6.5m PENALTY**

*** ADHERIUM TAKES FURTHER $750k BARVEST (TRUDELL) LOAN**

*** GOODBYE HEXIMA**

*** 4D MEDICAL PLEADS 'SCHULTZ, SHORTERS' TO ASX 27% PRICE DROP**

*** GZ FAMILY TAKE 15% OF ATOMO**

*** MESOBLAST TO LOSE CHAIR BURNS, DIRECTOR DR KRAUSE**

*** VITURA TO LOSE DIRECTOR SHANE TANNER; DIRECTOR WANTED**

MARKET REPORT

The Australian stock market fell 0.58 percent on Monday November 2, 2026, with the ASX200 down 51.6 points to 8,856.5 points. Eight of the Biotech Daily Top 40 companies were up, 25 fell, five traded unchanged and two were untraded.

Cyclopharm was the best, up 3.5 cents or 8.2 percent to 46 cents, with 283,801 shares traded. 4D Medical climbed 6.6 percent; Artrya and Orthocell were up more than three percent; Saluda and Syntara rose two percent or more; Medical Developments and Neuren were up more than one percent; with CSL up by 0.2 percent.

Proteomics led the falls, down 2.9 cents or 24.2 percent to 9.1 cents, with 993,303 shares traded. Aroa, EBR and Micro-X lost more than 11 percent; Botanix was down 10 percent; Compumedics shed 8.3 percent; Avita, Clarity, Curvebeam, Lumos, Prescient and Resmed were down five percent or more; Alcidion, Immutep, Mesoblast and Racura fell more than four percent; Imricor, Nanosonics, Nova Eye, Optiscan and Starpharma were down more than three percent; Actinogen, Emvision and Imugene shed more than two percent; Clinuvel, Cochlear and Pro Medicus were down one percent or more; with Telix down by 0.4 percent.

BIOTECH DAILY TOP 40 INDEX (BDI-40)

October did not shine on Australian biotechnology companies, despite including the Ausbiotech ‘biggest week in biotech’ on the Gold Coast in sunny Queensland.

The Biotech Daily Top 40 Index (BDI-40) fell 9.75 percent in October to a collective market capitalization of $18,783 million, with 30 companies down for the month, of which 24 fell more than 10 percent; just seven companies were up, with four up by more than 10 percent; and three were unchanged.

The $1,421 million fall in the BDI-20 included a $1,337 million fall by 4D Medical (down $582 million) and Telix (down $755 million) with just five of the BDI-20 companies improving. There is no explanation, yet, for 4D Medical’s 25.6 percent fall last Friday.

The benchmark ASX200 was up 1.4 percent to 8,908 points in October and the Nasdaq Biotechnology Index (NBI) rose 2.9 percent to 7,320 points – up 36.4 percent for the year.

The four Big Caps of Cochlear, CSL, Pro Medicus and Resmed, which are not included in the BDI-40, improved 8.9 percent to $174,608 million, 8.6 percent below last year.

Pro Medicus led the Big Caps, up $3,465 million or 20.2 percent to $20,590 million, followed by Resmed up $4,304 million or 9.4 percent to $49,941 million, CSL adding $6,373 million or 7.2 percent to end October at $94,777 million (not very far from the $100 billion mark), and Cochlear up $171 million or 1.9 percent to $9,300 million.

Avita was the best of October’s BDI-40 seven, up $225 million or 44.9 percent to $726 million, followed by Optiscan (14.9%), Nova Eye (13.2%), Mesoblast (10.2%), Resonance (2.9%), Nanosonics (1.7%) and Aroa (0.4%).


EBR led October's far too many falls, down $127 million or 53.6 percent to $110 million, followed by Starpharma (48.0%), Botanix (44.0%), Saluda (41.0%), Lumos (39.2%), Micro-X (37.2%), Immutep (32.0%), Orthocell (27.9%), Amplia (27.1%), Actinogen (24.9%), Artrya (23.2%), 4D Medical (22.8%), Curvebeam (21.05%), Prescient (20.8%), Clarity (20.4%), Atomo (18.75%), Racura (18.3%), Imricor (18.0%), Imugene (17.4%), Impedimed (16.7%), Medical Developments and Syntara (16.3%), Clinuvel (14.7%) and Telix (14.1%).

Outside the BDI-40, Cogstate was up 1.7 percent to $596 million, it's highest point in 12 months, with Blinklab and BLS holding steady.


The 11 companies in Cannabis & Psychedelics Corner fell 6.3 percent for the month – up 36.4 percent for the 12 months to October 31, 2026 - led by Nexalis (Inhalerx) down 50 percent to $2 million and Avecho down 26.0 percent to $54 million. Neurotech was the better of the two rises, up 17.4 percent to $23 million, with Cann group up 14.3 percent.

On the Nasdaq, Eyepoint (formerly Psivida) tumbled $353 million or 89.4 percent on a trial failure to $42 million, followed by Neuphoria (Bionomics) (14.3%), Kazia (12.0%) and Incannex (8.5%). Brisbane's Protagonist edged up 2.6 percent to $13,471 million.

BDI-40 v ASX200 Jun 30, 2006 to Oct 31, 2026- Adjusted



5-Year Big Caps $m (COH, CSL, PME, RMD) To Oct 31, 2026



LITTLE GREEN PHARMA

Little Green says receipts from customers for the six months to September 30, 2026 were up 113.0 percent to $49,739,000, compared to the prior corresponding period.
Little Green said receipts for the three months to September 30, 2026 rose 136.4 percent to $26,817,000, from sales of its medical marijuana products, with 81 percent from flower, 11 percent from oils and four percent, each, from edibles and vaporizers.
The company said about 65 percent of sales were through Cannatrek, with about 35 percent from Little Green branded marijuana products.
Earlier this year, Little Green said it had a scheme deed to merge with Cannatrek for marijuana cultivation and distribution (BD: Jan 18, May 25, 26, 2026).
The company said 82 percent of sales were in Australia, with the remaining 18 percent contribution from sales in Europe, with record cannabis flower imports in Germany of 67.6 tonnes of marijuana flower.
Little Green said cannabis flower was removed from German statutory health insurance reimbursement “however, the self-pay market appears largely unaffected by the changes and continues to drive market growth, as reflected in increasing import volumes”.
The company said it had a positive cash flow of $4,415,000 for the three months, with cash and cash equivalents of $22,310,000 at September 30, 2026 compared to $2,294,000 at September 30, 2025.
Little Green was unchanged at six cents with 1.35 million shares traded.

NEURIZON THERAPEUTICS

Neurizon says it will raise $4.3 million at 6.8 cents a share in a placement, with a further $2 million share plan to go and has settled 750,000 convertible notes.
Neurizon said the issue price was an 18.9 percent discount to the five-day volume weighted average price and a 20.9 percent discount to the last closing price.
The company said participants would receive one option for every share issued, exercisable at 12 cents each within 18 months from the issue date.
Neurizon said the funds were for its clinical and pre-clinical activities, manufacturing and supply-chain readiness, regulatory activities, business development and partnering opportunities as well as working capital.
The company said the placement included a $150,000 commitment from its board and management, subject to shareholder approval, with MST Financial Services and Morgans Corporate joint lead managers and bookrunners to the placement.
Neurizon said the share purchase plan had a record date of October 30, would open on November 16 and close on December 4, 2026.
The company said it had settled the remaining 750,000 Obsidian Global convertible notes on issue for $US915,750 ($A1,310,000), funded from its existing cash reserves.
Last year, Neurizon said it had a $20 million convertible note facility with New York’s Obsidian Global GP to fund its ‘Healey’ ALS platform trial (BD: Jan 18, 2026).
In September, the company said it would redeem 1,000,000 convertible notes held by Obsidian, leaving 750,000 notes outstanding (BD: Sep 10, 2026).
Today, Neurizon said no convertible notes were on issue and it had withdrawn resolution four from its annual general meeting, with no further drawdowns “until at least April 2027”.
The company said the redemption was intended to “simplify the company’s funding position, preserve funding optionality and ensure that future capital decisions are made having regard to the company's financial position, clinical progress, prevailing market conditions and the interests of existing shareholders”.
Neurizon fell 2.1 cents or 24.4 percent to 6.5 cents with 2.6 million shares traded.

PROTEOMICS INTERNATIONAL LABORATORIES

Proteomics says it hopes its share purchase plan raises $5,000,000 at 10 cents a share, a 12.2 percent discount to the five-day volume weighted average price,
Proteomics said the funds would be used for “commercial execution, clinical and reimbursement programs, product launch activities and US market readiness”.
The company said investors would receive one option for every share issued, exercisable at 15 cents each within two years, subject to shareholder approval.
Proteomics said the offer was not underwritten, had a record date of October 30, would open on November 4 and close on November 25, 2026.
Proteomics fell 2.9 cents or 24.2 percent to 9.1 cents.

NOXOPHARM

Noxopharm says it has “commitments” to raise $1.5 million at 4.2 cents a share in a placement, with a $1.0 million, non-underwritten share purchase plan to follow.
Noxopharm said the issue price was a 22.6 percent discount to the 15-day volume weighted average price and a 19.2 percent discount to the last traded price.
The company said chair Fred Bart had subscribed for $375,000, subject to shareholder approval at a meeting expected “in mid-December 2026”.
Noxopharm said investors would receive one option for every share issued, exercisable at 4.2 cents each by November 1, 2027, as well as one piggyback option for every attaching option exercised, exercisable at 6.3 cents by November 1, 2029.
The company said the funds were for an extension study of SOF-SKN in cutaneous lupus erythematosus, an investigational new drug application for a phase II trial, SOF-CAN and SOF-VAC pre-clinical work including in-vivo studies, and repayment of loans and notes.
Noxopharm said PAC Partners Securities was lead manager and bookrunner.
The company said the share plan had a record date of October 30, 2026, but did not disclose the opening date nor closing date.
Noxopharm said it had agreed to convert $3.78 million of convertible notes early, inclusive of interest, through the issue of 90,000,000 shares at 4.2 cents a share, representing 87 percent of existing notes on issue, subject to shareholder approval.
Last year, the company said its $2,600,000 noteholders approved the extension of the maturity date to January 2, 2027 (BD: Sep 23, 2025).
Noxopharm fell 0.4 cents or 7.7 percent to 4.8 cents.

ORTHOCELL

Orthocell says it has monthly record US Remplir sales of 92 units in October, up 84 percent on the average monthly sales and generating $279,000 in revenue.
Orthocell said the result was “the strongest month of US sales since launch and reflects growing surgeon adoption, increasing repeat utilization, an expanding network of actively selling distributor representatives and broader hospital access across key US markets”.
The company said the results showed “progress in converting expanded market access into increased product utilization and revenue”.
Orthocell managing-director Paul Anderson said October was “an important milestone in Orthocell’s US commercialization, with the groundwork laid over the past 12 months now translating into tangible revenue”.
“The improvement in key commercial indicators demonstrates that Remplir is gaining traction in the US market,” Mr Anderson said.
Orthocell was up two cents or 3.6 percent to 57 cents.

ANTERIS GLOBAL TECHNOLOGIES CORP

Anteris says its medium-size Duravr showed “single-digit mean gradients, large effective orifice areas, no moderate or severe para-valvular leaks and no valve related mortality”.
Anteris said the results included 30-day clinical and haemodynamic data from 22 patients with severe aortic stenosis with medium aortic annuli treated with its Duravr heart valve.
The company said its Duravr transcatheter heart valve “delivered a favorable haemodynamic profile with a large [effective orifice area] of 2.64 ± 0.19 cm^2 (baseline 0.8 ± 0.2 cm^2) and a single digit mean pressure gradient of 6.17 ± 1.40 [millimetres of mercury] (baseline 45.5 ± 11.7 [millimetres of mercury])”.
Anteris said at 30-days “clinical safety outcomes were positive with no valve related mortality and no moderate or severe paravalvular leak”, with no moderate or severe prosthesis-patient mismatch observed at 30 days.
Anteris said prosthesis-patient mismatch (PPM) happened when a prosthetic valve, after being implanted, did not have a large enough opening to accommodate the patient's blood flow needs, based on their body size; and the results showed “100 percent freedom from moderate-or-severe prosthesis-patient mismatch (PPM) in a cohort of medium annuli patients from the ‘Embark’ study”.
Anteris chief medical officer Dr Chris Meduri said the results were “exceptional 30-day haemodynamics for medium annuli, with large effective orifice areas, single-digit gradients, and no moderate or severe PPM or para-valvular leak”.
“That matters because prosthesis-patient mismatch is not just a small-annulus problem,” Dr Meduri said. “A recent study in younger, lower-risk [transcatheter aortic valve replacement] patients found PPM was associated with higher mortality and substantially more heart failure hospitalization at five years.”
“As [transcatheter aortic valve replacement] moves to patients who will live with their valve for decades, this is the haemodynamic profile we designed Duravr to deliver, and we look forward to ‘Paradigm’ confirming it in a randomized setting,” Dr Meduri said.
Anteris was up 32 cents or 3.6 percent to $9.15.

NEUREN PHARMACEUTICALS

Neuren says it has US Food and Drug Administration orphan drug designation for NNZ-2591 to treat neo-natal hypoxic-ischemic encephalopathy (HIE).
Neuren said the US designation was for drugs to treat a rare disease or condition with fewer than 200,000 patients and qualified it for “seven years of market exclusivity, as well as waiver of the prescription drug user fee for a marketing application”.
The company said hypoxic-ischemic encephalopathy was “a potentially devastating type of brain injury caused when a baby’s brain does not receive enough oxygen or blood flow before or shortly after birth”.
Neuren said it was conducting an FDA-required juvenile animal safety study, prior to a clinical trial and planned to submit an investigational new drug application by July 2027.
The company said it was developing NNZ-2591 for multiple indications, including Phelan-McDermid syndrome, Pitt Hopkins syndrome, hypoxic-ischemic encephalopathy and Angelman syndrome, all of which have orphan drug designation.
Neuren managing-director Jon Pilcher said the company was “pleased to receive the important commercial milestone of orphan drug designation”.
“We now look forward to discussing the development path with the FDA and preparing the [investigational new drug] application of a clinical study in HIE, a devastating condition with serious need,” Mr Pilcher said.
Neuren was up 39 cents or 1.9 percent to $20.75 with 574,227 shares traded.

PERCHERON THERAPEUTICS

Percheron says it has US Food and Drug Administration approval to begin the Vanderbilt Health-sponsored trial of HMBD-002 for blood cancers.

Last year, Percheron said it had licenced Singapore's Hummingbird Bioscience's HMBD-002 for cancer; and earlier this year, said Nashville, Tennessee's Vanderbilt Health would conduct a 38-patient trial of HMBD-002 for acute myeloid leukaemia and myelo-dysplastic syndrome (BD: Jun 26, 2025; Aug 28, 2026).

Last month, the company said it had completed HMBD-002 drug product manufacture to be used in the study (BD: Oct 23, 2026).

Today, Percheron managing-director Dr Michael Baker said the Vanderbilt study provided "an exciting opportunity to evaluate HMBD-002 in combination with venetoclax and azacitidine, two established [acute myeloid leukaemia] therapies".

"With HMBD-002 manufactured for the study and the FDA regulatory clearance now received, we are very pleased with the progress towards commencing this important clinical study," Dr Baker said.

Percheron was unchanged at 0.3 cents with 16.1 million shares traded.

ONCOSIL MEDICAL

Oncosil says it has filed to its European 'notified body for inclusion of Cyclotek's Sydney factory as a critical sub-contractor under its existing manufacturing certification.

Oncosil said the filing to the British Standards Institute (BSI) was "an important milestone … to establish a scalable, capital efficient manufacturing platform capable of supporting the increasing commercialization of the Oncosil device across international markets".

The company said the submission followed ISO13485 certification by Cyclotek in September, which confirmed Cyclotek's quality management system met the international standard for medical device manufacturing (BD: Sep 9, 2026).

Oncosil said the filing was "the next key step towards enabling commercial production of the Oncosil device at Macquarie Park, subject to the successful completion of the notified body's review and applicable approval processes", with Australian commercial manufacturing expected to begin by January 2028.

Oncosil was unchanged at 68 cents.

NEXSEN

Nexsen says it has ISO13485:2016 certification from the British Standards Institution (BSI) for its Strepsure group B Streptococcus diagnostic test.

Nexsen said the certification was the "internationally recognized quality management standard for medical devices, a core requirement for regulatory submissions and the standard expectation of commercial partners and distributors".

The company said the certification covered the design, development and manufacture of Strepsure and was an "important step in the … transition from research-led development towards commercialization".

Nexsen managing-director Mark Muzzin said it was "a major milestone for Nexsen and a significant step on Strepsure's path to market".

"ISO13485 is one of the core requirements for selling a medical device, and achieving it across design, development and manufacture gives regulators, hospitals and partners confidence that Strepsure is built within a quality system certified to an internationally recognized medical-device standard," Mr Muzzin said.

Nexsen was unchanged at 16 cents.

INOVIQ

Inoviq says Sonic Healthcare USA Inc will optimize and validate its Exo-OC ovarian cancer early detection test at its Rye Brook, New York laboratory.
Inoviq said the agreement provided “an option that may support future US commercialization as a laboratory developed test, subject to successful validation, exercise of the option and subsequent commercial discussions”.
The company said the deal was “a key step in Inoviq’s US commercialization strategy for Exo-OC” and that successful validation would be a “significant milestone toward making Exo-OC available in the US”; and the agreement terms were “confidential”.
Inoviq said it would collect samples across the US with “ovarian cancer specialists and hospitals to support clinical validation, regulatory and reimbursement activities … [and while progress would be] influenced by the availability of samples, conducting these activities in parallel is expected to streamline the pathway to commercialization”.
Inoviq said it expected the program would take about 12 months to 18 months.
Inoviq was up half a cent or 3.6 percent to 14.5 cents.

OSTEOPORE

Osteopore says it has concluded its orthopaedic products sales and marketing contract with Diethelm Keller Siber Hegner (DKSH) Singapore Pte Ltd, from December 31, 2026.
In 2024, Osteopore said Singapore and Vietnam approved its orthopaedic products for complex bone reconstruction and bone grafting procedures (BD: Mar 27, 2024).
Later, the company said DKSH would market and sell its off-the-shelf orthopaedic products in Singapore for five years (BD: Nov 6, 2024).
Today, Osteopore said its subsidiary would assume sales and marketing responsibility from January 1, 2027; and with DKSH its products had “gained adoption in a number of Singapore’s hospitals and clinics” in the past two years.
Osteopore said the decision to “directly manage the business comes from the need to strengthen focus for the Orthopaedic business in Singapore, streamlining and enhancing customer interaction and experience … [and was] important now with the establishment of Osteopore’s 3-[dimensional] printing services … and the upcoming introduction of the injectable regenerative bone filler, both of which target the same customer group”.
Osteopore was unchanged at 0.4 cents with five million shares traded.

VITURA HEALTH

Vitura says it is “not liable for the pecuniary penalty” of $6.5 million that CDA Clinics Qld Pty Ltd was ruled to pay in following a judgement in the Federal Court on Friday.
Last year, Vitura said it had “discontinued funding the defence of CDA Clinics [Queensland]” in the proceedings brought by the TGA (BD: Jan 19, 2025).
On Friday, the Therapeutic Goods Administration said CDA Clinics Queensland Pty Ltd had been ordered to pay $6.5 million and former director Dr Benjamin Jansen $450,000 in civil penalties “for the unlawful advertising of medicinal cannabis” (BD: Oct 30, 2026).
Today, Vitura said CDA Clinics QLD had entered liquidation in January 2025, and the pecuniary penalty would “be a claim in that liquidation”.
The company said it was “not liable for the pecuniary penalty, and the judgment has no financial impact on Vitura or its other subsidiaries”.
Vitura said “the proceedings relate to conduct … between April 27 and July 30, 2021 … [and] individuals involved in the conduct at that time are no longer with the company”.
Vitura fell 0.2 cents or 10 percent to 1.8 cents.

ADHERIUM

Adherium says it has taken an additional $750,000, unsecured loan at 12 percent a year interest from Barvest Ventures, repayable by October 26, 2027.
Last month, Adherium said it had a $700,000 loan from the London, Ontario-based major shareholder Trudell Medical-related Barvest Ventures Inc, at 12 percent annual interest, repayable by September 30, 2027 (BD:
Today, the company said the loan was separate from its existing $700,000 loan.
Adherium was untraded at 6.7 cents.

HEXIMA

Hexima has been removed from the ASX Official List following a $1 million capital return and four-to-one consolidation (BD: Mar 13, 2026).
Hexima last traded at 1.35 cents.

4D MEDICAL

4D Medical has told the ASX it is not aware of any information it has not announced which, if known, could explain the recent trading its securities.
The ASX said the company's share price fell 26.5 percent from $3.28 at the close of trading on Thursday October 29, 2026 to a low of $2.41 on Friday October 30, 2026, and noted a "significant increase" in the volume of securities traded.
4D Medical said that "to the best of its knowledge, the company believes an increase in short interest is responsible for the recent trading in its securities".
4D Medical was up 16 cents or 6.6 percent to $2.60 with 17.5 million shares traded.

ATOMO DIAGNOSTICS

Sydney's GZ Family Holdings says it has increased its substantial shareholding in Atomo from 116,922,671 shares (12.96%) to 131,602,671 shares (14.58%).
In a substantial shareholder form signed by GZ director Qixin Gao, GZ said it bought shares between August 19 and October 30, 2026, with the single largest purchase 3,680,000 shares on September 21 for $66,290, or 1.8 cents a share.
Atomo was unchanged at 1.4 cents with 10.8 million shares traded.

MESOBLAST

Mesoblast says chair William Burns and Dr Philip Krause will retire from the board at its annual general meeting, with Jane Bell appointed chair.
Mesoblast said Mr Burns had been a director for 12 years.
Mesoblast fell 10 cents or 4.4 percent to $2.16 with 5.5 million shares traded.

VITURA HEALTH

Vitura says non-executive director Shane Tanner has advised the board he wishes to retire, providing 90 days' notice, and that it is seeking to appoint a director.
Vitura said it had undertaken a review of its composition and skills matrix, which considered the capabilities required to support its priorities.
The company said it had begun a search for a replacement director.

BIOTECH DAILY TOP 40 WITH MARKET CAPITALIZATION AT OCT 31, 2026

Company $Am	Oct 31, 2025	Sep 30, 2026	Oct 31, 2026
Cochlear	18,665	9,129	9,300
CSL	87,114	88,404	94,777
Pro Medicus	27,522	17,125	20,590
Resmed	57,690	45,637	49,941
BDI-20			
4D Medical	891	2,557	1,975
Aroa	267	182	190
Avita	175	501	726
Clarity	1,793	783	623
Clinuvel	563	434	370
Compumedics	66	48	48
Cyclopharm	71	57	53
Dimerix	306	138	126
EBR Systems	549	237	110
Immutep	419	50	34
Imricor	457	568	466
Medical Developments	79	49	41
Mesoblast	3,220	2,740	3,019
Nanosonics	1,386	880	895
Neuren	2,775	2,580	2,553
Nova Eye	38	38	43
Orthocell	316	208	150
Polynovo	950	639	608
Syntara	49	43	36
Telix	5,477	5,343	4,588
Second 20			
Actinogen	111	217	163
Alcidion	124	148	148
Amplia	72	59	43
Artrya	514	582	447
Atomo	22	16	13
Botanix	266	50	28
Curvebeam	42	19	15
Emvision	170	148	140
Impedimed	77	18	15
Imugene	108	23	19
Lumos	161	97	59
Micro-X	73	43	27
Optiscan	125	141	162
Paradigm	180	153	153
Prescient	53	77	61
Proteomics	56	22	20
Racura Oncology	601	371	303
Resonance	23	34	35
Saluda	89	105	62
Starpharma	144	415	216

* Biotech Daily editor, David Langsam, owns shares in 4D Medical, Acrux, Actinogen, Alcidion, Amplia, Clarity, Cochlear, EBR, Nanosonics, Neuren, Patrys, Percheron, Polynovo and Telix, as well as unlisted and non-biotech stocks.
Through Australian Ethical Superannuation he has an indirect interest in other companies:
https://www.australianethical.com.au/personal/ethical-investing/companies-we-invest-in/. These holdings are liable to change.

Biotech Daily can be contacted at: PO Box 500, Flemington, Victoria, Australia, 3031
email: editor@biotechdaily.com.au; www.biotechdaily.com.au